Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review

Author:

Kapadia Ronak K12,Staples J Erin3,Gill Christine M4,Fischer Marc3,Khan Ezza5,Laven Janeen J3,Panella Amanda3,Velez Jason O3,Hughes Holly R3,Brault Aaron3,Pastula Daniel M136,Gould Carolyn V3

Affiliation:

1. Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine , Aurora, Colorado , USA

2. Division of Neurology, Department of Clinical Neurosciences, Cummings School of Medicine, University of Calgary , Calgary, Alberta , Canada

3. Division of Vector-Borne Diseases, Centers for Disease Control and Prevention , Fort Collins, Colorado , USA

4. University of Iowa, Carver College of Medicine, Department of Neurology , Iowa City, Iowa , USA

5. Hunterdon Infectious Disease Specialists , Flemington, New Jersey , USA

6. Department of Epidemiology, Colorado School of Public Health , Aurora, Colorado , USA

Abstract

Abstract With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Centers for Disease Control and Prevention. We identified 21 patients on recent rituximab therapy who were diagnosed with an arboviral disease caused by West Nile, tick-borne encephalitis, eastern equine encephalitis, Cache Valley, Jamestown Canyon, and Powassan viruses. All reported patients had neuroinvasive disease. The diagnosis of arboviral infection required molecular testing in 20 (95%) patients. Median illness duration was 36 days (range, 12 days to 1 year), and 15/19 (79%) patients died from their illness. Patients on rituximab with arboviral disease can have a severe or prolonged course with an absence of serologic response. Patients should be counseled about mosquito and tick bite prevention when receiving rituximab and other B-cell depleting therapies.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference43 articles.

1. Rituximab-related viral infections in lymphoma patients;Aksoy;Leuk Lymphoma,2007

2. Rituximab-associated infections;Gea-Banacloche;Semin Hematol,2010

3. Fatal case of chronic Jamestown Canyon virus encephalitis diagnosed by metagenomic sequencing in patient receiving rituximab;Solomon;Emerg Infect Dis,2021

4. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers;Dörner;Pharmacol Ther,2010

5. Past, present, and future of rituximab—the world's first oncology monoclonal antibody therapy;Pierpont;Front Oncol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3